Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification and structural characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3.

European journal of immunology - 1 Sept 2024

Sim Malcolm J W, Hanada Ken-Ichi, Stotz Zachary, Yu Zhiya, Lu Jinghua, Brennan Paul, Quastel Max, Gillespie Geraldine M, Long Eric O, Yang James C, Sun Peter D

Abstract excerpt

Mutations in KRAS are some of the most common across multiple cancer types and are thus attractive targets for therapy. Recent studies demonstrated that mutant KRAS generates immunogenic neoantigens that are targetable by adoptive T-cell therapy in metastatic diseases. To expand mutant KRAS-specific immunotherapies, it is critical to identify additional HLA-I allotypes that can present KRAS neoantigens and their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to KRAS gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-A3 Antigen

Share to Mice, Transgenic

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptors, Antigen, T-Cell

Source

Identifiers

PMID: 39030753
DOI: 10.1002/eji.202451079

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification and structural characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3.PMID 39030753Read ↗

Identification and Structural Characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3Semantic proximity Read ↗

Identification and affinity enhancement of T-cell receptor targeting a KRASG12V cancer neoantigen.Semantic proximity Read ↗

Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumorsSemantic proximity Read ↗

Functional avidity enhancement of a T-cell receptor targeting the KRASG12D cancer neoantigen.Semantic proximity Read ↗

KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumorsSemantic proximity Read ↗

Dual-degenerate TCRs target multiple KRAS hotspot and HLA-A3 family combinationsSemantic proximity Read ↗

Therapeutic potential of T cell receptor targeting the HLA-A*11:01-restricted KRASG12V neoantigen without cross-recognition of the self-antigen RAB7B in solid tumorsSemantic proximity Read ↗

Overcoming immune evasion from post-translational modification of a mutant KRAS epitope to achieve TCR-T cell-mediated antitumor activitySemantic proximity Read ↗

Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigenSemantic proximity Read ↗

Identification of novel KRASG12D neoantigen specific TCRs and a strategy to eliminate off-target recognitionSemantic proximity Read ↗

Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discoverySemantic proximity Read ↗

Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.